Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 501–600 of 911

A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
Okuma, Y., Hosomi, Y., Takahashi, S., Nakahara, Y., Watanabe, K., Nagamata, M., Takagi, Y., & Mikura, S. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3092-9 · Cited by 13
Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis
Bittner, N., Balikó, Z., Sárosi, V., László, T., Tóth, E., Kásler, M., & Géczi, L. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9955-2 · Cited by 13
Development and Validation of a Tool for Evaluating Core Competencies in Nursing Cancer Patients on Chemotherapy
Kim, S. H., & Park, J. H. (2012) · Journal of Korean Academy of Nursing · doi:10.4040/jkan.2012.42.5.632 · Cited by 13
Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells
Ikeda, R., Vermeulen, L. C., Lau, E., Jiang, Z., Kavanaugh, S. M., Yamada, K., & Kolesar, J. (2010) · Oncology Letters · doi:10.3892/ol.2010.198 · Cited by 13
Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists
Mazzone, P. J., & Mekhail, T. M. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.016 · Cited by 15
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Borget, I., Pérol, M., Pérol, D., Lavolé, A., Greillier, L., Dô, P., Westeel, V., Créquit, J., Léna, H., Monnet, I., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-953 · Cited by 12
A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients
Murphy, R. A., Clandinin, M. T., Chu, Q. S.-C., Arends, J., & Mazurak, V. C. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.05.013 · Cited by 12
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
Schultheis, B. S., Kummer, G., Zeth, M., Brendel, E., Xia, C., Kornacker, M., & Strumberg, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1685-x · Cited by 12
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
Cardona, A. F., Rojas, L., Wills, B., Arrieta, O. G., Carranza, H., Vargas, C. A., Otero, J. M., Cuello, M., Corrales, L., Martin, C. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154293 · Cited by 12
Changing costs of metastatic non small cell lung cancer in the Netherlands
Keusters, W. R., de Weger, V. A., Hövels, A. M., Schellens, J. H. M., & Frederix, G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.005 · Cited by 12
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach
Lee, S. W., Park, H., Lee, H. Y., Sohn, I., Lee, S.-H., Kang, J. K., Sun, J., & Ahn, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27273-9 · Cited by 12
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer
Okamoto, I., Yoshioka, H., Takeda, K., Satouchi, M., Yamamoto, N., Seto, T., Kasahara, K., Miyazaki, M., Kitamura, R., Ohyama, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318238154d · Cited by 12
Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution
İnal, A., Ma, K., Küçüköner, M., Urakçı, Z., Karakuş, A., & Işıkdoğan, A. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.4.1281 · Cited by 12
Triage of Cytologic Direct Smears for Ancillary Studies: A Case-Based Illustration and Review
Roh, M. H. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0235-cr · Cited by 12
A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research
Andronis, L., Billingham, L. J., Bryan, S., James, N. D., & Barton, P. M. (2015) · Medical Decision Making · doi:10.1177/0272989x15594369 · Cited by 13
A New BATTLE in the Evolving War on Cancer
Sequist, L. V. D., Muzikansky, A., & Engelman, J. A. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0044 · Cited by 12
EGFR mutations in non-small cell lung cancer: an audit from West China Hospital
Tang, Y., Wang, W.-Y., Zheng, K., Jiang, L., Zou, Y., Su, X., Chen, J., Zhang, W., & Liu, W.-P. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1199961 · Cited by 12
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
Chen, C., Chen, Y.-Y., Chen, J. J. W., Chen, K., Ho, C., Shih, J., Chang, Y., Yu, C., & Yang, P. (2017) · Oncotarget · doi:10.18632/oncotarget.18717 · Cited by 12
Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
Pujol, J., Roch, B., Roth, C. J., & Mérel, J.-P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197605 · Cited by 11
The Prognostic Significance Of JMJD3 In Primary Sarcomatoid Carcinoma Of The Lung, A Rare Subtype Of Lung Cancer
Li, S., Jiang, L., He, Q., Wei, W., Wang, Y., Zhang, X., Liu, J., Chen, K., Chen, J., & Xie, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s225596 · Cited by 12
The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review
Ganguli, A. X., Wiegand, P. N., Gao, X. Y., Carter, J. A., Botteman, M. F., & Ray, S. (2012) · Quality of Life Research · doi:10.1007/s11136-012-0229-0 · Cited by 12
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer
Okamoto, I., Yamamoto, N., Kubota, K., Ohe, Y., Nogami, N., Murakami, H., Yamaya, H., Ono, K., & Nakagawa, K. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9674-9 · Cited by 12
Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
Imai, H., Kaira, K., Mori, K. P., Ono, A., Akamatsu, H., Taira, T., Yoshino, R., Kenmotsu, H., Saitoh, J., Harada, H., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-0929-3 · Cited by 12
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy
Kim, J., Cho, C.-K., & Yoo, H. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416639714 · Cited by 12
Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer
Fernández‐López, C., Expósito‐Hernández, J., Arrebola, J. P., Calleja‐Hernández, M. Á., Ruíz, M. E., Tejada, R. G., Linares, I., & Cabeza-Barrera, J. (2016) · Cancer Medicine · doi:10.1002/cam4.782 · Cited by 11
Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
Murray, N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3448 · Cited by 12
Second-Line Therapy in Non–Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
Zer, A., & Leighl, N. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4270 · Cited by 12
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison
Qi, W., Tang, L., He, A., Shen, Z., Lin, F., & Yao, Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.675880 · Cited by 11
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
Schmid‐Bindert, G., Gebbia, V., Mayer, F., Arriola, E., Márquez-Medina, D., Syrigos, K., Biesma, B., Leschinger, M. I., Frimodt‐Moller, B., Ripoche, V., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.010 · Cited by 11
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
Minami, S., Kijima, T., Takahashi, R., Kida, H., Nakatani, T., Hamaguchi, M., Takeuchi, Y., Nagatomo, I., Yamamoto, S., Tachibana, I., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-296 · Cited by 11
First-, Second- and Third-Line Lung Cancer Treatment Patterns And Associated Costs in a US Healthcare Claims Database
Ramsey, S. D., Henk, H. J., Smith, G. L., Sollano, J., & Chen, C. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.12 · Cited by 11
New basic approach to treat non‐small cell lung cancer based on RNA ‐interference
Makowiecki, C., Nolte, A., Sutaj, B., Keller, T., Avci‐Adali, M., Stoll, H., Schlensak, C., Wendel, H. P., & Walker, T. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12065 · Cited by 11
First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients
Louis, R., Rajendranath, R., Ganesan, P., Sagar, T., & Krishnamurthy, A. (2012) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.103141 · Cited by 11
Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer
Urquhart, G., Kerr, K. M., Nicolson, M. C., Loo, P. S., Sharma, R. D., Shrimali, R. K., & Petty, R. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000016 · Cited by 11
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Chen, C., Lin, J., Huang, J., Chen, K., Shih, J., Yu, C., & Yang, P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.001 · Cited by 11
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting
Shah, M., Winfree, K. B., Peterson, P. M., Gruschkus, S. K., Eaddy, M. T., & Green, M. R. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.021 · Cited by 11
Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients
Song, Z., Yu, Y., Chen, Z., & Lü, S. (2010) · Medical Oncology · doi:10.1007/s12032-010-9753-3 · Cited by 11
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
Lal, R., Bourayou, N., Hillerdal, G., Nicolson, M. C., Vikström, A., Lorenzo, M., Dyachkova, Y., Barriga, S., & Visseren‐Grul, C. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-163 · Cited by 11
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)
Seifert, H., Georgiou, A., Alexander, H. R., McLachlan, J., Bodla, S., Kaye, S. B., Barton, D. P. J., Nobbenhuis, M., Gore, M. E., & Banerjee, S. N. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.015 · Cited by 11
A methoxyflavanone derivative from the Asian medicinal herb (Perilla frutescens) induces p53-mediated G2/M cell cycle arrest and apoptosis in A549 human lung adenocarcinoma
El‐Hafeez, A. A. A., Fujimura, T., Kamei, R., Hirakawa, N., Baba, K., Ono, K., & Kawamoto, S. (2017) · Cytotechnology · doi:10.1007/s10616-017-0116-1 · Cited by 12
Surgical approach in oligometastatic non-small cell lung cancer
Patrini, D., Panagiotopoulos, N., Bedetti, B., Mitsos, S., Crisci, R., Solli, P., Bertolaccini, L., & Scarci, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.16 · Cited by 11
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
Aguilar, K. M., Winfree, K. B., Muehlenbein, C. E., Zhu, Y. E., Wilson, T., Wetmore, S., & Nadler, E. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0811-0 · Cited by 11
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
Park, K., Kim, J.-S., Kim, J.-H., Kim, Y., Kim, H., Cho, E. K., Jin, J., Kim, M., Märten, A., & Kang, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08445-9 · Cited by 11
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer
Nishiyama, A., Katakami, N., Yoshioka, H., Iwasaku, M., Korogi, Y., Hata, A., Takeshita, J., Otsuka, K., Nishino, K., Uchida, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.017 · Cited by 13
Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study
Bylicki, O., Ferlay, C., CHOUAID, C., Lavolé, A., Barlési, F., Dubos, C., Westeel, V., Créquit, J., Corre, R., Vergnenégre, A., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828cb505 · Cited by 11
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer
Luo, J., Leaw, S. J., Xu, Y., & Zheng, D. (2010) · Medical Oncology · doi:10.1007/s12032-010-9575-3 · Cited by 11
Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer
Pirl, W., Traeger, L., Greer, J., Jackson, V., Lennes, I., Gallagher, E., Sequist, L., & Temel, J. (2013) · Palliative & Supportive Care · doi:10.1017/s1478951512001071 · Cited by 11
Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
Chen, J., Li, X., & Wei, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s45148 · Cited by 11
A novel high‐resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA
Minárik, M., Gassmann, M. G., Belšánová, B., Pešek, M., Schouten, J., Chudoba, R., Gaš, B., & Benešová, L. (2010) · Electrophoresis · doi:10.1002/elps.201000156 · Cited by 10
Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
Shen, G., Bian, G., Yu, H., Gao, M., Kang, D., Shen, G., & Hu, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.210 · Cited by 10
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease
Mariano, C. J., Bosdet, I., Karsan, A., Ionescu, D. N., Murray, N., Laskin, J. J., Zhai, Y., Melosky, B. L., Sun, S. B., & Ho, C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.007 · Cited by 10
Self-citation
Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study
de Marinis, F., Ardizzoni, A., Fontanini, G., Grossi, F., Cappuzzo, F., Novello, S., Santo, A., Lorusso, V., Cortinovis, D. L., Iurlaro, M., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.04.004 · Cited by 10
Commercial Laboratory Testing of Excision Repair Cross-Complementation Group 1 Expression in Non-Small Cell Lung Cancer
Schneider, J. G., Farhadfar, N., Sivapiragasam, A., Geller, M. D., Islam, S., & Selbs, E. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0311 · Cited by 10
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
Paz-Ares, L. G., Zimmermann, A. H., Ciuleanu, T., Bunn, P. A., Antonio, B. S., Denne, J. S., Iturria, N. L., John, W. J., & Scagliotti, G. V. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.007 · Cited by 10
Lung Cancer in the Era of Targeted Therapy: A Cytologist's Perspective
Zakowski, M. F. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0029-ra · Cited by 10
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience
Kato, Y., Hotta, K., Takigawa, N., Nogami, N., Kozuki, T., Satô, A., Ichihara, E., Kudo, K., Oze, I., Tabata, M., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2425-9 · Cited by 10
Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer: A Phase II Study
Takiguchi, Y., Seto, T., Ichinose, Y., Nogami, N., Shinkai, T., Okamoto, H., Minato, K., Seki, N., Eguchi, K., Kishi, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c76a · Cited by 10
Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China
Shi, J., & Zhu, J. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0356-9 · Cited by 10
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Lü, S., Cheng, Y., Zhou, C., Wang, J., Yang, J. C., Zhang, P.-H., Zhang, X., Wang, X., Orlando, M., & Wu, Y.-L. L. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.04.003 · Cited by 10
The impact of heterogeneity in phosphoinositide 3-kinase pathway in human cancer and possible therapeutic treatments
Wang, W., Lv, J., Wang, L., Wang, X., & Ye, L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.024 · Cited by 10
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC
Langhammer, S., & Scheerer, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16674 · Cited by 9
Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells
Shang, B., Jia, Y., Chen, G., & Wang, Z. (2017) · Respiratory Research · doi:10.1186/s12931-017-0545-6 · Cited by 10
Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand
Limwattananon, C., Limwattananon, S., Waleekhachonloet, O., & Rattanachotphanit, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.003 · Cited by 11
Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer
Wallrabenstein, T., del Rio, J., Templeton, A. J., & Buess, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233768 · Cited by 10
Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells
Ikeda, R., Vermeulen, L. C., Jiang, Z., Lau, E., & Kolesar, J. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.130 · Cited by 10
A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection
Okuma, Y., Tanuma, J., Kamiryo, H., Kojima, Y., Yotsumoto, M., Ajisawa, A., Uehira, T., Nagai, H., Takeda, Y., Setoguchi, Y., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1956-8 · Cited by 10
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Zukin, M. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1590/s0104-42302012000200025 · Cited by 10
Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review)
Kim, Y. H., Nagai, H., Ozasa, H., Sakamori, Y., & Mishima, M. (2013) · Biomedical Reports · doi:10.3892/br.2013.151 · Cited by 10
What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer
Bridges, C. M., & Smith, E. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2317-x · Cited by 10
A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer
Yang, Y., Chang, J., Huang, C., Zhang, Y., Wang, J., Shu, Y., Burillon, J. P., Riggi, M., Pétain, A., Ferré, P. J., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.22 · Cited by 10
Anti-proliferation evaluation of new derivatives of indole-6-carboxylate ester as receptor tyrosine kinase inhibitors
Allawi, M. M., Mahmood, A. A. R., Tahtamouni, L. H., Saleh, A. M., Kanaan, S. I., Saleh, K. M., AlSakhen, M. F., Himsawi, N. M., & Yasin, S. R. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2347084 · Cited by 9
A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer
Takata, M., Chikumi, H., Matsunami, K., Kodani, M., Sakamoto, T., Hashimoto, K., Nakamoto, M., Okada, K., Kitaura, T., Matsumoto, S., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3716 · Cited by 9
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Lu, J., & Ramirez, R. A. (2017) · PubMed Central · Cited by 9
Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma
Hernández, A. S., Juan, Ó., Vidal-Martínez, J., Blanco, R., Maciá, S., Galiana, G. E., Aparisi, F., Noguera, J. G., Catot, S., Gaspà, F. L., et al. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1223-5 · Cited by 9
Management of non-small-cell lung cancer in the older adult
Vanderwalde, A. M., Pal, S. K., & Reckamp, K. L. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.01.008 · Cited by 9
First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review
Chen, Y.-M., Whang‐Peng, J., & Chen, C. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.04.008 · Cited by 9
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents
Jiang, J., Liang, X., Zhou, X., Huang, R., Chu, Z., & Zhan, Q. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1294-z · Cited by 9
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study
on behalf of LIFE study team, Gridelli, C., de Marinis, F., Ardizzoni, A., Novello, S., Fontanini, G., Cappuzzo, F., Grossi, F., Santo, A., Cortinovis, D. L., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1715-2 · Cited by 9
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents
Bao, R., & Chan (2011) · Journal of Experimental Pharmacology · doi:10.2147/jep.s7804 · Cited by 9
Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study
Min, K., Kim, W. S., Jang, S. J., Choi, Y. D., Chang, S. H., Jung, S. H., Kim, L., Roh, M. S., Lee, C. S., Shim, J. W., et al. (2015) · QJM · doi:10.1093/qjmed/hcv103 · Cited by 9
Ceritinib: A primer for pharmacists
Au, T. H., Cavalieri, C. C., & Stenehjem, D. D. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216672315 · Cited by 8
18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients
Bai, L., Guo, C., Wang, J., Liu, X., Li, Y., Li, M., Guo, Y., & Duan, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s113832 · Cited by 9
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias
Snyders, K., Cho, D., Hong, J. H., Lord, S. J., Asher, R., Marschner, I. C., & Lee, C. K. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1674452 · Cited by 9
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non–small cell lung cancer: IFCT-1201 MODEL trial
Quoix, É., Audigier-Valette, C., Lavolé, A., Molinier, O., Westeel, V., Barlési, F., Treut, J. H. L., Pichon, É., Dauba, J., Otto, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.034 · Cited by 9
Comparing Effectiveness with Efficacy: Outcomes of Palliative Chemotherapy for Non-Small-Cell Lung Cancer in Routine Practice
Harrison, L. D., Zhang‐Salomons, J., Mates, M., Booth, C. M., King, W. D., & Mackillop, W. J. (2015) · Current Oncology · doi:10.3747/co.22.2419 · Cited by 9
Are Clinical Guidelines Applied in Routine Daily Practice? A French Regional Survey of Physicians' Clinical Practices in Lung Cancer Management (EPOTRA)
Couraud, S., Fournel, P., Moro‐Sibilot, D., Pérol, M., & Souquet, P.-J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.04.003 · Cited by 9
The Role of Maintenance Treatment in Advanced Non–Small-Cell Lung Cancer: Reality or Early Second Line?
Gridelli, C., Rossi, A., Maione, P., Ambrosio, R., Barbato, V., Bareschino, M. A., Schettino, C., Palazzolo, G., & Sacco, P. C. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.049 · Cited by 9
Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Reckamp, K. L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.041 · Cited by 9
Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas
Sinna, E. A., Ezzat, N. E.-S., & Sherif, G. M. (2013) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2013.05.005 · Cited by 9
Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia
Rubovszky, G., Nagy, T., Gődény, M., Szász, A., & Láng, I. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9551-7 · Cited by 9
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: A retrospective cohort study
Langer, C. J., Ravelo, A., Hazard, S. J., Guérin, A., Ionescu‐Ittu, R., Latrémouille-Viau, D., Wu, E. Q., & Ramalingam, S. S. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.017 · Cited by 9
Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better…
Maïo, M. D., Morabito, A., Piccirillo, M. C., Daniele, G., Giordano, P., Costanzo, R., Sandomenico, C., Montanino, A., Rocco, G., & Perrone, F. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660762 · Cited by 8
Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population
Han, X., Zhang, Z., Wu, D., Shen, Y., Wang, S., Wang, L., Liu, Y., Yang, S., Hu, X., Feng, Y., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.10.008 · Cited by 9
Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy
Nakashima, K., Murakami, H., Omori, S., Wakuda, K., Ono, A., Kenmotsu, H., Naito, T., Endo, M., & Takahashi, T. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1001 · Cited by 9
Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb
Fischer, J. R., Griesinger, F., Fink, T., Salm, T., Marseille, A., & Wolf, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.006 · Cited by 8
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
Oki, Y., Hirose, T., Yamaoka, T., Kusumoto, S., Shirai, T., Sugiyama, T., Okuda, K., Nakashima, M., Murata, Y., Ohmori, T., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1382-1 · Cited by 8
2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model
Mumper, R. J., Peng, L., Schorzman, A. N., Benhabbour, S. R., Ma, P., Madden, A., & Zamboni, W. C. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s66040 · Cited by 8
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)
Belvedere, O., Follador, A., Rossetto, C., Merlo, V., Defferrari, C., Sibau, A. M., Aita, M., Bello, M. G. D., Meduri, S., Gaiardo, M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.020 · Cited by 8
The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer
Sheng, J., Yang, Y., Zhao, Y., Qin, T., Hu, Z.-H., Zhou, T., Zhang, Y., Hong, S., Ma, Y., Zhao, H., et al. (2015) · Medicine · doi:10.1097/md.0000000000001400 · Cited by 8
Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed
Magali, L., Pascal, F., Aho, S., Boulin, M., Zouak, A., Tinel, C., & Mousson, C. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02935-8 · Cited by 8

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks